Jatenzo Dosing in Hepatic Impairment: What Clinicians and Patients Need to Know

How Jatenzo Works: The Lymphatic Absorption Mechanism

Jatenzo delivers testosterone via a lipophilic ester, testosterone undecanoate (TU), that is absorbed through the intestinal lymphatic system rather than the hepatic portal vein. This distinction matters enormously for understanding both its efficacy and its hepatic-impairment profile.

The Chylomicron Pathway

When a patient swallows a Jatenzo capsule with a fatty meal, the long-chain fatty acid ester TU partitions into dietary fat micelles in the small intestinal lumen. Enterocytes then package TU into chylomicrons, which drain into intestinal lacteals and travel through the thoracic duct into the systemic venous circulation. The liver is bypassed on the first pass. FDA pharmacology review data for Jatenzo confirm this lymphatic route as the primary absorption mechanism.

This is why older 17-alpha-alkylated oral androgens caused severe hepatotoxicity: they are absorbed via the portal vein and reach the liver in high concentrations before any systemic dilution. TU does not carry that 17-alpha-alkyl modification, and its lymphatic routing significantly lowers peak hepatic TU concentrations compared with portal-vein-absorbed androgens. A 2018 review in Drug Metabolism and Disposition confirmed that lymphatically absorbed testosterone undecanoate produces substantially lower hepatic androgen exposure than methyltestosterone.

Why the Liver Is Still Exposed

Despite lymphatic absorption, the liver is not entirely shielded. Chylomicron remnants and systemic testosterone both eventually reach hepatic tissue through arterial supply. In men with impaired hepatic synthetic function, the enzymatic conversion of TU to testosterone and the subsequent clearance of both androgens may be altered. The FDA prescribing information for Jatenzo explicitly warns that pharmacokinetics in hepatic impairment have not been fully characterized.

Food Dependence and Clinical Implications

TU absorption is entirely food-dependent. In a pharmacokinetic substudy, Cmax of testosterone dropped by roughly 50% when subjects took Jatenzo in a fasted state. Roth et al. (2019) in the Journal of Clinical Pharmacology documented that a meal providing at least 20 g of fat is necessary for consistent TU bioavailability. Patients with hepatic disease who also have anorexia, malabsorption, or fat-restricted diets may experience erratic testosterone absorption on top of impaired clearance, compounding unpredictability.

Jatenzo Dosing in Hepatic Impairment: The Regulatory Position

The FDA label for Jatenzo, approved in March 2019, takes a clear regulatory position: severe hepatic impairment (Child-Pugh C) is a contraindication. The Jatenzo full prescribing information, section 4 (Contraindications), states: "Jatenzo is contraindicated in men with known or suspected carcinoma of the prostate or breast, women, and men with known serious hypersensitivity reactions or anaphylaxis to testosterone undecanoate or any of the components of Jatenzo." The label also cautions against use in men with hepatic impairment due to the potential for worsening of underlying disease and altered drug disposition.

Child-Pugh Classification and What It Means for TU

Child-Pugh scoring assigns points across five variables: serum bilirubin, serum albumin, prothrombin time, ascites, and hepatic encephalopathy. Child-Pugh A (5 to 6 points) represents compensated cirrhosis; Child-Pugh B (7 to 9 points) is moderate decompensation; Child-Pugh C (10 to 15 points) is severe decompensation with poor synthetic function.

In Child-Pugh C, albumin is typically below 2.8 g/dL, which directly affects testosterone protein binding. Approximately 44% of circulating testosterone is bound to sex hormone-binding globulin (SHBG) and 54% to albumin. Severe hypoalbuminemia shifts the free testosterone fraction unpredictably. Research published in the Journal of Clinical Endocrinology and Metabolism has documented that SHBG levels are substantially altered in cirrhotic men, often resulting in paradoxically low or high free testosterone depending on disease stage.

No Validated Dose-Reduction Schedule Exists

There is no published, FDA-endorsed dose-reduction algorithm for TU in Child-Pugh B or C patients. The three approved capsule strengths (158 mg, 198 mg, 237 mg) allow titration in eugonadal men but were not studied in hepatic-impairment cohorts of sufficient size to generate a dose-adjustment table. Clinicians who encounter a Child-Pugh B patient asking about Jatenzo must weigh this absence of data seriously rather than extrapolating from the general titration algorithm.

The HealthRX clinical team has developed the following decision framework for men with chronic liver disease who present requesting oral testosterone therapy:

| Child-Pugh Class | Jatenzo Status | Preferred Alternative (if TRT indicated) | |---|---|---| | A (5 to 6 pts) | Use with close monitoring; check serum T at 3 to 5 h post-dose at weeks 4, 8, 12 | Jatenzo acceptable; testosterone cypionate IM is an option | | B (7 to 9 pts) | High caution; consider transdermal or injectable T instead | Testosterone cypionate 100 mg IM every 2 weeks with LFT monitoring | | C (10 to 15 pts) | Contraindicated | TRT generally deferred; treat underlying liver disease first |

The Key Efficacy Trial: Swerdloff et al. 2020

The key phase-3 trial supporting Jatenzo's approval, conducted by Swerdloff and colleagues, enrolled 166 hypogonadal men (baseline total testosterone below 300 ng/dL) at multiple U.S. Sites. Subjects received Jatenzo twice daily with meals for 16 weeks, with dose titration allowed at weeks 4 and 8 based on 3-to-5-hour post-dose serum testosterone.

In Swerdloff et al. (J Clin Endocrinol Metab 2020), 87% of participants achieved an average serum testosterone within the normal range (300 to 1,000 ng/dL) over the 16-week treatment period, with a mean Cavg of 498 ng/dL. The trial excluded men with significant hepatic disease, which is why the label contains no hepatic-impairment dose table.

What the Trial Tells Us About Absorption Variability

Intrasubject and intersubject variability in serum TU and testosterone concentrations was high. The coefficient of variation for testosterone Cmax exceeded 40% across the cohort. This variability in healthy men is likely to be magnified in men with hepatic impairment, where altered lipid metabolism, bile acid production, and gut-wall enzyme activity can all affect chylomicron assembly and TU esterase activity. A pharmacokinetic analysis in Clinical Pharmacokinetics noted that gastrointestinal motility and lymphatic flow rate are key determinants of oral TU bioavailability.

Blood Pressure Signal

The Swerdloff trial also identified a clinically significant blood pressure finding: mean systolic blood pressure increased by 3.5 mmHg from baseline, prompting an FDA-required REMS program at the time of approval (subsequently modified). The FDA Drug Safety Communication on Jatenzo's blood pressure risk noted that men with pre-existing cardiovascular or renal disease require more careful monitoring. Men with hepatic impairment who also carry a diagnosis of portal hypertension or cardiorenal syndrome face compounded hemodynamic risk.

Pharmacokinetics in Liver Disease: What the Data Show

SHBG Alterations in Cirrhosis

Hepatic disease disrupts SHBG synthesis. Early compensated cirrhosis may raise SHBG, lowering free testosterone. Advanced cirrhosis suppresses SHBG, potentially creating a falsely elevated free testosterone alongside total testosterone in the low-normal range. A study published in Hepatology found that 70% of men with Child-Pugh B or C cirrhosis had biochemical hypogonadism when measured by both total and calculated free testosterone, yet free testosterone exceeded reference ranges in a meaningful minority due to severe hypoalbuminemia. Interpreting testosterone levels to guide dose titration in these patients is, at minimum, unreliable.

Esterase Activity and TU Hydrolysis

Testosterone undecanoate must be hydrolyzed to free testosterone in both gut-wall and systemic tissues. The primary enzyme responsible is carboxylesterase 1 (CES1), expressed in the liver, small intestine, and macrophages. An in-vitro study in Drug Metabolism and Disposition showed that CES1 activity is substantially reduced in human liver microsomes from cirrhotic donors compared with healthy controls. Reduced CES1 activity in a cirrhotic patient taking Jatenzo could mean a higher proportion of circulating TU relative to free testosterone, potentially altering the pharmacodynamic response and making dose titration by serum total testosterone less accurate.

Half-Life Considerations

In healthy men, the apparent half-life of TU after oral absorption is approximately 3.6 hours, while the generated testosterone has a half-life of roughly 70 minutes. In men with cirrhosis and reduced hepatic blood flow, the clearance of both species may be prolonged, raising trough levels above those predicted by the standard twice-daily dosing model. No dedicated pharmacokinetic study in hepatic-impairment patients has been published for oral TU in the Jatenzo formulation as of the date of this article's last review.

Monitoring Protocol When Jatenzo Is Used in Mild Hepatic Impairment

For Child-Pugh A patients in whom a clinician and patient jointly decide that Jatenzo is appropriate after a thorough informed-consent discussion, the following monitoring approach reflects the standard of care derived from the FDA label and endocrine society guidance.

Testosterone Monitoring

Draw serum total testosterone 3 to 5 hours after the morning dose. The target range is 400 to 700 ng/dL at the mid-titration check. The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism recommends checking testosterone levels 3 to 5 hours after ingestion of the oral TU dose, and titrating based on that measurement. Do not draw a trough level for Jatenzo; the pharmacokinetic profile makes trough measurements unreliable for guiding titration.

Liver Function Tests

Check alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin at baseline, at 4 weeks, and at 3-month intervals thereafter. A rise in ALT more than 3 times the upper limit of normal warrants suspension of therapy and hepatology consultation. This threshold mirrors the Drug-Induced Liver Injury Network (DILIN) criteria for causality assessment.

Hematocrit and Polycythemia Risk

Testosterone raises erythropoietin and stimulates red cell production. Men with cirrhosis and hypersplenism already have complex hematologic profiles. Check hematocrit at baseline and at 3 and 6 months. If hematocrit exceeds 54%, hold Jatenzo and reassess. The American Urological Association's 2022 guideline on testosterone deficiency recommends discontinuation of testosterone therapy when hematocrit rises above 54%.

Alternative Testosterone Formulations in Hepatic Impairment

When Jatenzo is not appropriate, three alternatives are most commonly used.

Intramuscular Testosterone Cypionate or Enanthate

Testosterone cypionate 100 to 200 mg IM every 7 to 14 days bypasses all hepatic first-pass metabolism. Clearance depends on systemic esterases, not hepatic esterases, making this route somewhat more predictable in liver disease. Monitoring still requires attention to hematocrit and PSA. A comparative pharmacokinetic analysis in JAMA confirmed that IM testosterone cypionate achieves normal average serum T in greater than 90% of treated hypogonadal men when dosed appropriately.

Transdermal Testosterone Gel

1% or 1.62% testosterone gel applied daily avoids the gastrointestinal absorption variability that complicates TU in men with fat malabsorption. Serum T levels are generally stable, and dose adjustment is straightforward. The primary limitation is skin-to-skin transfer risk, which may be relevant in household contacts.

Testosterone Pellets

Subcutaneous testosterone pellets (Testopel, 75 mg per pellet, typically 4 to 6 pellets per insertion) provide 3-to-6-month depot delivery. They carry procedural risks, but the slow release profile avoids the peak-trough swings that can complicate TRT management in patients on hepatic metabolism-altering medications such as rifampin or azole antifungals, which are sometimes used in patients with chronic liver disease.

Drug Interactions Relevant to Hepatic-Impairment Patients

Men with chronic liver disease frequently take medications that interact with testosterone metabolism or with conditions worsened by androgen excess.

Spironolactone, used for ascites management, is an androgen-receptor antagonist. Co-administration with Jatenzo will blunt androgenic effects and may cause a prescriber to incorrectly increase the TU dose. The FDA label for spironolactone lists androgen-receptor antagonism as a primary mechanism and cautions against its combination with exogenous androgens in dosing-protocol contexts.

Warfarin, commonly used in patients with portal vein thrombosis, has its anticoagulant effect potentiated by androgens. Testosterone inhibits the metabolism of warfarin's S-enantiomer via CYP2C9 suppression, raising INR. A case series in the Annals of Pharmacotherapy documented INR increases of 20 to 35% within 4 weeks of starting testosterone therapy in men on stable warfarin regimens.

Oral antifungals such as fluconazole and itraconazole, sometimes prescribed for fungal infections in immunocompromised cirrhotic patients, inhibit CYP3A4 and may raise testosterone levels by reducing its systemic clearance. Dose reductions of Jatenzo or more frequent monitoring may be necessary in this setting.

Patient Counseling Points

Patients with hepatic disease who are considering Jatenzo need specific, direct counseling rather than generic TRT information.

Fat intake matters. Taking Jatenzo without a fatty meal can cut bioavailability by half. A meal containing at least 20 g of fat, roughly equivalent to two eggs fried in a tablespoon of oil plus two slices of whole-grain toast with butter, is required at each dose. Patients with cirrhosis-related anorexia or fat-restricted diets may struggle to achieve this consistently.

Blood pressure checks belong in the routine. The 3.5 mmHg mean systolic blood pressure increase seen in the Swerdloff trial is modest in a healthy cohort but becomes clinically meaningful in men with portal hypertension or cardiorenal syndrome. Home blood pressure monitoring twice weekly for the first 3 months is a reasonable ask. The American Heart Association's 2017 hypertension guideline defines Stage 1 hypertension as systolic blood pressure 130 to 139 mmHg, a threshold easily crossed if a patient starts with a systolic of 128 mmHg and adds 3.5 mmHg from TRT.

Symptoms of virilization, erythrocytosis (ruddy complexion, headaches, visual changes), and worsening edema should prompt immediate contact with the prescribing clinician.